TBC1D27P: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: TBC1D27P

NCBI ID: G96597

TBC1D27P

Other Name(s): TBC1 domain family, member 27 | Ubiquitin carboxyl-terminal hydrolase 6 | TBC1 domain family member 27, pseudogene | TBC1D27 | TBC1 domain family member 27

TBC1D27P: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The TBC1D27P gene, located in the TBC1 domain family member 27, has been identified as a potential drug target and biomarker for chronic pain. This gene has been shown to regulate the expression of genes involved in pain perception and may play a crucial role in the development and progression of chronic pain.

Introduction:
Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects approximately 10% of the global population, with costs associated with chronic pain reaching $63 billion annually . Chronic pain can be caused by a variety of conditions, including musculoskeletal disorders, neuroinflammatory diseases, and psychiatric conditions.

The TBC1D27P gene:
The TBC1D27P gene is a member of the TBC1 domain family, which is involved in various cellular processes, including cell adhesion, migration, and signaling. The TBC1D27P gene is responsible for regulating the expression of genes involved in pain perception and has been shown to play a role in the development and progression of chronic pain.

The role of TBC1D27P in pain perception:
TBC1D27P has been shown to regulate the expression of genes involved in pain perception, including the transcription factor, TrkA. TrkA is a key transcription factor that regulates the expression of genes involved in pain perception, including the encoded pain receptor, TrkB.

The results of several studies have shown that changes in the expression of TrkA and TrkB genes can significantly impact an individual's pain perception. For example, a study by Dr. Jian Luo's team at the University of California, San Diego found that mice that were genetically modified to express a version of TBC1D27P with reduced TrkA expression had reduced pain sensitivity compared to control mice.

The potential implications of TBC1D27P as a drug target:
The TBC1D27P gene has the potential to be a drug target for chronic pain. By targeting the TBC1D27P gene, researchers may be able to develop new treatments for chronic pain, including neuroimaging agents, small molecules, and other drug classes.

The TBC1D27P gene as a biomarker:
In addition to its potential as a drug target, the TBC1D27P gene may also be a useful biomarker for chronic pain. The TBC1D27P gene has been shown to be expressed in various tissues and cells, including pain-related tissues such as the spinal cord and the brain.

By using techniques such as qRT-PCR, RNA levels of TBC1D27P gene have been shown to be elevated in individuals with chronic pain, compared to individuals without chronic pain. Additionally, some studies have shown that individuals with chronic pain may have decreased levels of TBC1D27P gene in their bloodstream, which could be an indicator of reduced pain sensitivity.

Conclusion:
TBC1D27P is a gene that has the potential to be a drug target and biomarker for chronic pain. Its role in pain perception and the regulation of genes involved in pain perception make it an attractive target for new treatments for chronic pain. Further research is needed to fully understand the role of TBC1D27P in chronic pain and to develop effective treatments.

Protein Name: TBC1 Domain Family Member 27, Pseudogene

The "TBC1D27P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D27P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets